Pharma feed

N
Novartis AG
FiercePharma· 06 Dec 2019

FDA greenlights generics of Novartis' $3B MS star Gilenya amid legal fight

In June, a U.S. district court judge temporarily shielded Novartis’ $3 billion-a-year multiple sclerosis (MS) drug Gilenya from generic competition—but that’s not preventing generics makers from lining up at the starting gate. Thursday, the FDA approved the first three generic versions of Gilenya, which will be made by HEC Pharm, Biocon and Sun Pharmaceutical.

  • Novartis AG
  • Regulatory and Legal
  • Press Releases
  • News and Other Websites
Novartis AG
Express Pharma· 06 Dec 2019

US FDA approves generic versions of Novartis blockbuster MS treatment

The US Food and Drug Administration approved three generic versions of Swiss drugmaker Novartis AG’s top-selling multiple sclerosis (MS) medicine Gilenya. The approval allows HEC Pharm Co, Biocon and Sun Pharmaceutical Industries to produce the drug for the treatment of relapsing forms of MS in adult patients.

  • Novartis AG
  • Regulatory and Legal
  • Company Websites
Sanofi
Sanofi· 06 Dec 2019

Sanofi at the Women’s Forum, Paris

Gender gaps in society remain a major barrier worldwide, impeding social advancement and hampering economic growth. To address these gaps, Sanofi has launched an ambitious commitment to achieve equal representation of women and men among its senior leaders.

  • Sanofi
  • New Offerings
  • Company Websites
Allied Market Research
Novartis· 06 Dec 2019

Clinical Development Manager

Job Description Your responsibilities: Your responsibilities include, but are not limited to: 1. Act as the project leader of the clinical trial (internal and external team) and execute trial in accordance with project strategy 2. Contribute clinical research and operational expertise in the development of clinical trial design; 3.

  • Allied Market Research
  • Novartis AG
  • Clinical Trials
  • Company Websites
Novartis AG
Novartis· 06 Dec 2019

Specialist Representative

Job Description - To build and execute business plans to meet sales goals for assigned territory. - To drive territory sales performance, market share and optimal resource utilization. - To develop effective professional business relationships with customers that support delivery of business results across a range of therapeutic areas.

  • Novartis AG
  • Financial and Business Performance
  • Company Websites
N
U.S. Food and Drug Administration
The Economic Times· 06 Dec 2019

U.S. FDA approves generic versions of Novartis blockbuster MS treatment

The U.S. Food and Drug Administration on Thursday approved three generic versions of Swiss drugmaker Novartis AG's top-selling multiple sclerosis (MS) medicine Gilenya.The approval allows HEC Pharm Co Ltd, Biocon Ltd and Sun Pharmaceutical Industries Ltd to produce the drug for the treatment of relapsing forms of MS in adult patients.Novartis was defending patents on Gilenya in the United States to block generic rivals.Earlier in June, U.S.

  • U.S. Food and Drug Administration
  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Eli Lilly and Co
The Economic Times· 06 Dec 2019

Eli Lilly to put Loxo executives in charge of new cancer research unit

By Carl O'DonnellU.S. drugmaker Eli Lilly and Co said on Thursday it will create a new cancer research division that will be run by top executives from Loxo Oncology, a cancer-focused biotech company it acquired

  • Eli Lilly and Co
  • Loxo Oncology, Inc.
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Eli Lilly and Co
BioSpace· 06 Dec 2019

BioSpace Movers & Shakers, Dec. 6

Eli Lilly – Indianapolis-based Eli Lilly announced new leadership in its oncology R&D business. The company will combine the Lilly Research Laboratories (LRL) oncology organization and Loxo Oncology, which was acquired by Eli Lilly in early 2019.

  • Eli Lilly and Co
  • Biospace
  • Management Changes
  • M&A Activities
  • News Articles
  • News and Other Websites
N
Amgen, Inc.
Contify Life Science News· 06 Dec 2019

FDA Approves Amgen's AVSOLA (infliximab-axxq), For The Same Indications As Remicade (infliximab)

THOUSAND OAKS, California, Dec. 6 -- Amgen issued the following news release: - Amgen's Fourth FDA Approval From Biosimilars Portfolio Amgen (NASDAQ:AMGN) today announced that the U.S.

  • Amgen, Inc.
  • Regulatory and Legal
  • News Articles
  • Licensed Content
N
Sanofi
Medpage Today· 06 Dec 2019

Toujeo OK'd for Kids; NDMA Worries for Metformin; Unhealthy Store Receipts?

This article is a collaboration between MedPage Today and: Sanofi said the FDA approved an expanded indication for insulin glargine injection (Toujeo) to include pediatric patients with type 1 and type 2 diabetes ages 6 and older.

  • Sanofi
  • Partnerships and Alliances
  • News Articles
  • News and Other Websites
N
Alexion Pharmaceuticals Inc
Biopharma Dive· 06 Dec 2019

We're not for sale, Alexion executives declare

Dive Brief: Alexion Pharmaceuticals said it will not ask bigger companies to acquire it. Instead, company executives said they believe their strategy of switching patients from an older product to a newer one, as well as experimental drugs in development, will drive more value through sales growth than would an acquisition.

  • Alexion Pharmaceuticals Inc
  • M&A Activities
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
Children's Hospital
Citybizlist· 06 Dec 2019

Bayer Enters into Collaboration with Children's Hospital of Philadelphia

Bayer announced today that it has entered into a three-year collaboration agreement with Children's Hospital of Philadelphia (CHOP) for the discovery and development of small molecules (SMOLs) to develop a first-in-class oral non-replacement therapy (NRT) for the treatment of hemophilia A and B.

  • Children's Hospital
  • Bayer AG
  • Partnerships and Alliances
  • Procurement and Sales
  • News Articles
  • News and Other Websites
N
Takeda Pharmaceutical Co Ltd
Pharmabiz· 06 Dec 2019

Takeda, Enzyre to develop device to determine coagulation status at home

Enzyre, which is developing breakthrough ambulant diagnostic technology for coagulation testing, announced that it has entered into a research collaboration agreement with Takeda Pharmaceutical Company Limited (Takeda) to develop a diagnostic device that will enable hemophilia patients to determine their coagulation status at home.

  • Takeda Pharmaceutical Co Ltd
  • Partnerships and Alliances
  • News Articles
  • News and Other Websites
N
Allergan Inc
Pharmabiz· 06 Dec 2019

Allergan announces positive phase 3 ACHIEVE I trial results for ubrogepant

Allergan plc announced that positive results from ACHIEVE I (UBR-MD-01), a robust phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the December 5th issue of The New England Journal of Medicine (NEJM).

  • Allergan Inc
  • Clinical Trials
  • News Articles
  • News and Other Websites
N
McKinsey & Co Inc
Medical Marketing & Media· 06 Dec 2019

The Escalator: W2O names two board members

W2O names board members Pharma executive Jonathan Peacock and advertising and digital marketing leader George Gallate have joined W2O’s board of directors. Peacock has worked in leadership roles at Novartis, Amgen and McKinsey. Gallate formerly led Havas Digital and Merkle.

  • McKinsey & Co Inc
  • Havas Media
  • Amgen, Inc.
  • Novartis AG
  • W2O Group
  • Management Changes
  • News Articles
  • News and Other Websites
N
Novartis AG
Drug Store News· 06 Dec 2019

Dr. Reddy's debuts 2 generics

Dr. Reddy’s is launching deferasirox tablets for oral suspension. The product is the generic of Novartis’ Exjade (deferasirox) tablets for oral suspension. The Exjade brand had a market value of roughly $113 million for the most recent 12 months ending in September 2019, according to IQVIA.

  • Novartis AG
  • IQVIA
  • New Offerings
  • News Articles
  • News and Other Websites
N
Best Buy Co Inc
FirstWord Pharma· 06 Dec 2019

Johnson & Johnson Names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of Directors

"I am very pleased to welcome Hubert Joly and Mark Weinberger to Johnson & Johnson's Board of Directors," said Alex Gorsky, Chairman and Chief Executive Officer. "Both of these accomplished leaders possess global expertise across many industries and will bring their strategic insights to Johnson & Johnson.

  • Best Buy Co Inc
  • Johnson & Johnson
  • Management Changes
  • News Articles
  • News and Other Websites
  • Biogen Inc
  • Events
  • Social Updates
  • Twitter
N
Pfizer Inc.
Seeking Alpha· 06 Dec 2019

Surveilling The Laggards Part 4: Merck Nears Late 2000 All-Time High, While Pfizer Restructures For Growth

Source: YCharts The above chart shows the decade return for Merck (NYSE:MRK), Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY), and while this article is about Merck and Pfizer, readers can see how the large-cap pharma space has kept pace with the key benchmark for the 2010 decade.

  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bankruptcy
  • News Articles
  • News and Other Websites
N
Allergan Inc
GuruFocus· 06 Dec 2019

John Paulson’s Top 5 Buys in the 3rd Quarter

John Paulson (Trades, Portfolio), manager of Paulson & Co., disclosed in a quarterly portfolio report that his firm’s top five buys for the third quarter included new positions in Callon Petroleum Co. (NYSE:CPE) and Presidio Inc.

  • Allergan Inc
  • Paulson & Co Inc
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
U.S. Food and Drug Administration
Menafn· 06 Dec 2019

Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma

(MENAFN - PR Newswire) RARITAN, N.J., Dec. 6, 2019 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy in previously treated patients with multiple myeloma.

  • U.S. Food and Drug Administration
  • Johnson & Johnson
  • Janssen Pharmaceuticals Inc
  • Procurement and Sales
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
  • Catalent Inc
  • Financial and Business Performance
  • Social Updates
  • Twitter
N
Bristol-Myers Squibb Co
Pharmabiz· 06 Dec 2019

Bristol-Myers Squibb's ORENCIA receives US FDA breakthrough therapy designation

Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ORENCIA (abatacept) for the prevention of moderate to severe acute graft-versus-host disease (GvHD) in hematopoietic stem cell transplants from unrelated donors.

  • Bristol-Myers Squibb Co
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Best Buy Co Inc
FirstWord Pharma· 06 Dec 2019

Johnson & Johnson Names Hubert Joly, Executive Chairman of Best Buy and Mark A. Weinberger, Former EY Global Chairman and CEO to its Board of Directors

"I am very pleased to welcome Hubert Joly and Mark Weinberger to Johnson & Johnson's Board of Directors," said Alex Gorsky, Chairman and Chief Executive Officer. "Both of these accomplished leaders possess global expertise across many industries and will bring their strategic insights to Johnson & Johnson.

  • Best Buy Co Inc
  • Johnson & Johnson
  • Management Changes
  • News Articles
  • News and Other Websites
N
Novartis AG
FirstWord Pharma· 06 Dec 2019

FDA approves first generic versions of Novartis' MS drug Gilenya

The FDA said Thursday that it has approved three marketing applications from Sun Pharmaceutical, Biocon and HEC Pharm for the first generics of Novartis' Gilenya (fingolimod) to treat relapsing forms of multiple sclerosis (MS) in adults.

  • Novartis AG
  • Biocon Ltd
  • Sun Pharmaceutical Industries
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
1 2 3 4 5